Pricing Log in Create free account
Saturday 17 October 2026 Export CRVO’s income statement to Excel — free account

CervoMed Inc.

CRVO Healthcare Biotechnology

CervoMed Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 million, down 58.9% from fiscal 2024. In the quarter to June 2026, revenue fell 99.6%, EPS grew 8.57% and free cash flow fell 6.20%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

2.24 0.01 −0.44%
Market cap
$34.0M
P/E
0.0×
Fwd P/E
−1.1×
Dividend yield
—
F-score
2/9
Altman Z
0.28
Beneish M
−4.94
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 3.74
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy 10 — — — — — — 1 — — — —
Sell — — — — — — — — — — — —
Insider Ownership 5.32%

Capital & Financial Ratios $m

Market Cap 34.02
Revenue 4.01
Net Income (30.35)
Free Cash Flow (27.98)
Net Debt (24.94)
Current Ratio 8.57 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (1.09) (negative: loss-making)
P/S ratio 5.73
P/B ratio 1.00
Past 5Y EPS Growth —
This Y EPS Growth 27.74% (at or above 15%: strong)
Next Y EPS Growth 31.18% (at or above 15%: strong)
Next Y revenue growth (96.67%) (below 0%: weak)
Next 5Y EPS Growth 28.27% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.7×, against a ten-year median of 6.1×; over the ten years it ranged from −0.9× in 2023 to 19.4× in 2024.
P/S against its own 10 years 28.76%
10-year low 10-year high
P/B against its own 10 years 40.33%
10-year low 10-year high
EV/Sales against its own 10 years 8.87%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 8 39 21 25
Receivables 1 2 0 —
Inventory — — — —
Other — — — —
10 43 23 26
2023 2024 2025 Q'26
Payables 1 2 1 1
ST’ Debt — — — —
Other — — — —
3 4 5 3

Compound Annual Growth %

10y 5y 3y
Sales — — —
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% (5.99%) 0.00%

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’25 2 2 0 0 4
’24 2 3 2 2 10
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (8) (7) — — —
’25 (4) (7) (6) (7) (23)
’24 (1) (2) (5) (8) (17)
’23 (1) (2) (1) (3) (7)
’22 (5) (4) 7 (1) (3)
’21 (5) (3) (3) (3) (15)
’20 (4) (3) (4) (3) (14)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (8) (7) — — —
’25 (4) (7) (6) (7) (23)
’24 (1) (2) (5) (8) (17)
’23 (1) (2) (1) (3) (7)
’22 (5) (4) 7 (1) (3)
’21 (5) (3) (3) (3) (14)
’20 (4) (3) (4) (3) (14)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.86) (0.64) — — —
’25 (0.56) (0.70) (0.84) (0.88) (2.98)
’24 (0.41) (0.27) (0.55) (0.80) (2.02)
’23 (1.03) (2.75) 0.57 2.40 (0.82)
’22 (3.33) (3.09) (2.05) (3.09) (11.20)
’21 (4.50) (3.00) (9.00) (3.00) (18.75)
’20 (5.25) (7.50) (5.25) (4.50) (22.50)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 900.00 1,192.50 137.25 15.75 18.75 21.75 6.96 4.14 1.80 1.92

Analyst estimates 2026–2028

Powerpack
High 19,125.00 17,437.50 2,340.00 825.00 120.00 138.75 30.00 14.37 26.38 16.94
People
People Employees 10 11 10 10 13 16 13 8 15 15
Revenue/emp, $m 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.89 0.65 0.27
Income, $m
Income, $m Revenue — — — — — — — 7 10 4
Gross margin, % 0.00 0.00 0.00 0.00 0.00 0.00 — 100.00 100.00 100.00
EBT (18) (2) (19) (11) (16) (25) (6) (2) (16) (27)
EBT margin, % 0.00 0.00 0.00 0.00 0.00 0.00 0.00 (30.40) (167.29) (673.07)
Net income (18) (1) (18) (12) (14) (24) (6) (2) (16) (27)
Depreciation 0 0 7 0 0 0 — — — —
Per share, $
Per share, $ Revenue 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.69 1.21 0.44
Earnings (1,978.91) (236.12) (615.72) (131.99) (22.50) (18.75) (11.47) (0.82) (2.02) (2.98)
Cash flow (1,183.33) (1,121.13) (249.37) (110.27) (18.88) (11.17) (4.97) (2.80) (2.05) (2.59)
Capex (0.25) (40.71) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Free cash flow (1,183.58) (1,161.84) (249.37) (110.27) (18.88) (11.17) (4.97) (2.80) (2.05) (2.59)
Book value 1,009.31 1,929.99 361.38 225.22 34.57 26.89 (17.37) 2.77 4.86 2.02
Shares, m 0 0 0 0 1 1 1 3 8 9
Valuation, ×
Valuation, × P/E — — — — — — — 0.00 0.00 0.00
P/S — — — — — — — 2.98 1.94 17.83
P/B — — — — — — — 2.89 0.48 3.92
EV/Sales — — — — — — — 3.70 (0.73) 15.86
EV/FCF — — — — — — — (3.35) 0.42 (2.66)
Cash, $m
Cash, $m Operating cash flow (11) (12) (11) (10) (14) (15) (3) (7) (17) (23)
Capex 0 0 — — — 0 — — — —
Free cash flow (11) (13) (11) (10) (14) (14) (3) (7) (17) (23)
Balance, $m
Balance, $m Working capital (3) 7 8 13 16 35 3 7 39 18
Total debt 2 1 — 0 0 — 12 — — —
Net debt 1 (8) (8) (14) (18) (37) 8 (8) (39) (21)
Shareholders’ equity 9 21 16 20 25 35 (9) 7 39 18
Returns, %
Returns, % ROA (182.55) (12.00) (120.07) (55.77) (62.25) (73.50) (27.64) (30.74) (61.41) (81.77)
ROIC (114.12) (55.05) (155.49) (118.50) (157.62) 0.00 0.00 0.00 (4,064.19) 0.00
ROE (394.54) (17.21) (144.53) (66.02) (71.80) (80.69) (713.60) 16.77 (69.95) (93.92)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Dec 2025

Charts ten years each

CervoMed Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
EDSA Edesa Biotech, Inc. $36.1M — (loss-making) — (loss-making) −99.88% (below 0%: shrinking) n/m −81.24% (below 0%: shrinking) 0.00% 0.00% Compare
NNVC NanoViricides, Inc. $35.0M — (loss-making) — — n/m −23.94% (below 0%: shrinking) 0.00% 0.00% Compare
LIANY LianBio Sponsored ADR $34.2M 0.0× — — n/m +1,107.59% (above 0%: growing) 0.00% 0.00% Compare
CRVO CervoMed Inc. $34.0M — (loss-making) — (loss-making) −99.60% (below 0%: shrinking) n/m −6.20% (below 0%: shrinking) 100.00% 0.00%
IRLA Quince Therapeutics, Inc. $33.8M — (loss-making) — — n/m −63.65% (below 0%: shrinking) 0.00% 0.00% Compare
ALGS Aligos Therapeutics, Inc. $33.7M — (loss-making) — (loss-making) +2,778.55% (above 0%: growing) n/m −59.81% (below 0%: shrinking) 100.00% (6.80%) Compare
ATNM Actinium Pharmaceuticals, Inc. $33.3M 3.1× — (loss-making) +77,677.78% (above 0%: growing) n/m −4.91% (below 0%: shrinking) 100.00% 78.76% Compare
BCTX BRIACELL THERAP $32.8M 1.5× — — n/m +0.21% (above 0%: growing) 0.00% 0.00% Compare
GNTA Genenta Science S.p.A. Unsponsored ADR $32.3M — — — — +35.94% (above 0%: growing) 0.00% — Compare
Median of peers $33.7M 1.5× — +2,778.55% — −14.42% 0.00% 0.00%

All 614 Biotechnology stocks →

CervoMed Inc. (CRVO) key facts

  • Concern: CervoMed Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 million, down 58.9% from fiscal 2024.
  • CervoMed Inc. (CRVO) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, CRVO traded at $2.24, a market capitalization of $34.0 million.
  • Return on equity was −93.9% and debt-to-equity 0.00.
  • Its Piotroski F-score is 2 out of 9 and its Altman Z-score is 0.28 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

CervoMed Inc. (CRVO) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/CRVO · Data as of Dec 31, 2025 · For information only; not investment advice. · © 2026 stockrow.com